Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › ACET

Adicet Bio

ACET Rare disease Lead: Phase 1 5 Biotech Distilled articles ↓ 25 filings & releases ↓ Cash $27.1M (Sep 30, 2026) ↓ 5 verdicts ↓ 10 timing quotes ↓
ImmunologyNeurologyOncologyRenal Cell

Market cap $28.6M 9.4M shares (10-Q, Nov 3, 2026) × $3.05 close Nov 6, 2026

Most recent annual filing: 2026-03-12

Catalyst timeline

8 trackedQuarter catalyst calendar →
  1. Prula-cel RA Ph1 interim2H 2026Prula-cel RA Ph1 interim, 2H 2026, material
  2. Prula-cel / pivotal program start2H 2026Prula-cel / pivotal program start, 2H 2026, notable
  3. in vivo CAR-T platform readout2H 2026in vivo CAR-T platform readout, 2H 2026, notable
  4. ADI-212 trial start4Q 2026ADI-212 trial start, 4Q 2026, routine
  5. Prula-cel interim1Q 2027Prula-cel interim, 1Q 2027, material
  6. Systemic sclerosis (SSc) program readout1H 2027Systemic sclerosis (SSc) program readout, 1H 2027, notable
  7. In vivo CAR-T pipeline corporate2H 2027In vivo CAR-T pipeline corporate, 2H 2027, routine
  8. in vivo candidate corporate update2H 2027in vivo candidate corporate update, 2H 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (8 active programs)

Technology platforms

In Vivo CAR-T

In vivo CAR-T platform designed to optimize in vivo T-cell transduction and generate highly cytolytic CAR-T therapy; preclinical programs targeting multiple myeloma, non-Hodgkin's lymphoma, and solid tumor indications; first candidate expected to enter clinic in 2H/2027.

Targets: BCMA, CD19

Discontinued (1)

Capital (as filed)

Cash
$27.1M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$73.8M Sep 30, 2026
Operating cash flow
−$17.9M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$101M cash, runway the second half of 2027 per the update of Nov 5, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (5)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (5 calls)

Every verdict Biotech Distilled has published on Adicet Bio, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-08-07 Watch Adicet Bio (ACET) — Scientific Deep Dive for Prula-cel, ADI-212 and Pipeline Products Mechanism is de-risked and receipts are better than most, but cash cushion is thin, eGFR data is concerning, and an unreconciled enrollment line in the MD&A warrants waiting for the 3Q/2026 readout before positioning.
  2. 2026-08-27 Watch UPDATE: Adicet Bio (ACET) - The Second Asset Clears ADI-212 IND clearance validates management's calendar but does not change the binary; the defining catalyst remains the 3Q/2026 prula-cel 22-patient readout, and the 13.6% run compresses risk/reward without answering key questions.
  3. 2026-09-02 Watch UPDATE: Adicet Bio (ACET) - The Clock Is Set Last patient visit complete and topline guided to September 2026 defuses the enrollment red flag and tightens the timeline, but the binary is unchanged and trim-pre-binary discipline applies now for existing holders.
  4. 2026-09-29 Watch UPDATE: Adicet Bio (ACET) - The Denominator Speaks The 22-patient readout showed regression to the mean (50% CRR vs. implied 100%), the mechanism and safety held, a single-arm pivotal was blessed, but the financing gap to a 2029 readout now dominates and the cleaner entry may be alongside the specialists in the upcoming raise.
  5. 2026-11-06 Watch UPDATE: Adicet Bio (ACET) - The Going Concern Arrives A going-concern warning, ADI-212 enrollment slip, and stock at ~$2.92 (deeply below $100.9M cash) make any equity raise severely dilutive; the science is unchanged but the financing gap is now the dominant risk, and the patient approach is to wait for the company to price its deal before stepping in.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (10 quotes from 6 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (25)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 27, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

11 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)